fbpx

molecules of the month

ABBV-744

BD2 domain selective BET inhibitor

orally efficacious in XG w/o platelet, GI tox

from SBDD of BD1/2 dual inhibitors

Nature, 2020, 578, 306-310

AbbVie, North Chicago, IL

ABBV-744
1 min read

ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: